Trial drug can significantly block early stages of COVID-19 in engineered human tissues. An international team has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. Source 9h
COVID-19 vaccine candidate shows promise, research shows. Scientists have announced a potential vaccine against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic. When tested in mice, the vaccine -- delivered through a fingertip-sized patch -- produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus. Source 4b.
Possible cure for COVID-19: Remdesivir.
The US has pledged as much as $1.2 billion to get early access to 300 million doses of an experimental COVID-19 vaccine. A possible coronavirus vaccine being developed by the University of Oxford and licensed to British drugmaker AstraZeneca got the United States' largest vote of confidence to date in terms of funds pledged. The vaccine could be delivered as early as October, though that only means the doses will be stored until the vaccine completes clinical trials ensuring it is safe and effective in protecting against COVID-19 infection. Ref. USAToday.
Who should get the COVID-19 vaccine first? Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19. Source 7n.
Oxford University’s COVID-19 vaccine trials halted following an ‘unexplained illness'. Drug giant AstraZeneca is reviewing the "Single event" that caused the illness during Phase 3 of Oxford's coronavirus vaccine trials. The interruption represents the first major hiccup in what has been a smooth path in the rapid vaccine effort spanning the globe. Ref. USAToday.